<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833894</url>
  </required_header>
  <id_info>
    <org_study_id>ARGX-113-2006</org_study_id>
    <nct_id>NCT04833894</nct_id>
  </id_info>
  <brief_title>Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis</brief_title>
  <official_title>Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>argenx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>argenx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod&#xD;
      IV in children and adolescents aged from 2 to less than 18 years of age with gMG.&#xD;
&#xD;
      Trial details include:&#xD;
&#xD;
        -  The maximum trial duration for each individual participant will be approximately 28&#xD;
           weeks&#xD;
&#xD;
        -  The treatment duration will be 8 weeks for the dose-confirmatory part (Part A) and 18&#xD;
           weeks for the treatment response-confirmatory part (Part B)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 30, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efgartigimod concentrations as input for compartmental, model-driven analysis to determine (age and size dependency of) Clearance (CL)</measure>
    <time_frame>up to 26 weeks</time_frame>
    <description>Blood samples will be collected from each participant for measurement of serum concentrations of efgartigimod</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efgartigimod concentrations as input for compartmental, model-driven analysis to determine (age and size dependency of) Volume of Distribution (Vd)</measure>
    <time_frame>up to 26 weeks</time_frame>
    <description>Blood samples will be collected from each participant for measurement of serum concentrations of efgartigimod</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Immunoglobulin G (IgG) levels as input for pharmacokinetics (PK) and pharmacodynamics (PD) modeling analysis</measure>
    <time_frame>up to 26 weeks</time_frame>
    <description>Total Immunoglobulin G levels will be measured from blood samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-acetylcholine receptors antibodies (AChR-Ab) as input for pharmacokinetics (PK) and pharmacodynamics (PD) modeling analysis</measure>
    <time_frame>up to 26 weeks</time_frame>
    <description>Total Immunoglobulin G (IgG) levels will be measured from blood samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)</measure>
    <time_frame>up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efgartigimod serum concentrations from blood samples</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of levels of total Immunoglobulin G (IgG) from blood samples</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of levels of total Immunoglobulin G (IgG) from blood samples</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline of total Immunoglobulin G (IgG) from blood samples</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADAs) against efgartigimod in serum samples</measure>
    <time_frame>up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of anti-drug antibodies (ADAs) against efgartigimod in serum samples</measure>
    <time_frame>up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of total Myasthenia Gravis Activity of Daily Living (MG-ADL) score. Total score can range from 0 to 24, with higher total scores indicating more impairment.</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Myasthenia Gravis Activity of Daily Living (MG-ADL) score. Total score can range from 0 to 24, with higher total scores indicating more impairment.</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of total Quantitative Myasthenia Gravis Score (QMG score). The total possible score is 39, where higher total scores indicate more severe impairments.</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total Myasthenia Gravis Score (QMG score). The total possible score is 39, where higher total scores indicate more severe impairments.</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of total score EuroQoL 5 Dimensions Youth (EQ-5D-Y)</measure>
    <time_frame>up to 26 weeks</time_frame>
    <description>Description of the participant's health state is done by digits for 5 dimensions combined in a 5-digit number. A unique health state is defined by combining 1 level from each of the 5 dimensions. Each state is referred to in terms of a 5-digit code, whereas code 11111 would indicate no problems in any of the 5 dimensions and 33333 would indicate worst problems in any of the 5 dimensions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total score EuroQoL 5 Dimensions Youth (EQ-5D-Y)</measure>
    <time_frame>up to 26 weeks</time_frame>
    <description>Description of the participant's health state is done by digits for 5 dimensions combined in a 5-digit number. A unique health state is defined by combining 1 level from each of the 5 dimensions. Each state is referred to in terms of a 5-digit code, whereas code 11111 would indicate no problems and 33333 would indicate worst problems in any of the 5 dimensions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Values of Neurological Quality of Life (Neuro-QoL) pediatric fatigue questionnaire</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Neurological Quality of Life (Neuro-QoL) pediatric fatigue questionnaire</measure>
    <time_frame>up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in protective antibody titers to vaccines received before or during the trial from blood samples</measure>
    <time_frame>up to 28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Generalized Myasthenia Gravis</condition>
  <arm_group>
    <arm_group_label>Efgartigimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving efgartigimod intravenous (IV) treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Efgartigimod IV</intervention_name>
    <description>Intravenous infusion of Efgartigimod</description>
    <arm_group_label>Efgartigimod</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability of the participant and/or his/her legally authorized representative to&#xD;
             understand the requirements of the trial and provide written informed consent/assent,&#xD;
             if applicable (including consent/assent for the use and disclosure of research-related&#xD;
             health information), willingness and ability to comply with the trial protocol&#xD;
             procedures (including attending the required trial visits).&#xD;
&#xD;
          2. Male or female participants between 2 to less than 18 years of age at the time of&#xD;
             providing informed consent/assent. Age groups are enrolled in a staggered fashion&#xD;
             respectively: 6 participants in the 12 to less than 18 years of age group followed by&#xD;
             6 participants in the 2 to less than 12 years of age group at the time of providing&#xD;
             informed consent/assent.&#xD;
&#xD;
          3. Diagnosed with Generalized Myasthenia Gravis (gMG) with confirmed documentation&#xD;
&#xD;
          4. Meeting the clinical criteria as defined by the Myasthenia Gravis Foundation of&#xD;
             America (MGFA) class II, III, and IVa.&#xD;
&#xD;
          5. Eligible participants should have an unsatisfactory response (efficacy and/or safety)&#xD;
             to immunosuppressants, steroids or acetylcholinesterase (AChE) inhibitors and should&#xD;
             be on stable concomitant Generalized Myasthenia Gravis (gMG) therapy of adequate&#xD;
             duration before screening.&#xD;
&#xD;
          6. Positive serologic test for acetylcholine receptor (anti-AChR) antibodies at screening&#xD;
             (for younger participants (&lt;15kg) historical values can be used).&#xD;
&#xD;
          7. Contraceptive use should be consistent with local regulations regarding the methods of&#xD;
             contraception for those participating in clinical trials. A subject is of childbearing&#xD;
             potential if, in the opinion of the investigator, he/she is biologically capable of&#xD;
             having children and is sexually active.&#xD;
&#xD;
               1. Male participants: Male participants must agree to not donate sperm from the time&#xD;
                  the informed consent form was signed until the end of the trial.&#xD;
&#xD;
               2. Female participants: Female adolescents of childbearing potential must have a&#xD;
                  negative serum pregnancy test at screening and a negative urine pregnancy test at&#xD;
                  baseline before investigational medicinal product (IMP) can be administered.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants with Myasthenia Gravis Foundation of America (MGFA) class I, IVb, and V.&#xD;
&#xD;
          2. Female adolescents of childbearing potential (FAOCBP): Pregnancy or lactation, or the&#xD;
             participant intends to become pregnant during the trial or within 90 days after the&#xD;
             last dose of investigational medicinal product (IMP).&#xD;
&#xD;
          3. Has any of the following medical conditions:&#xD;
&#xD;
               1. Clinically significant uncontrolled active or chronic bacterial, viral, or fungal&#xD;
                  infection at screening.&#xD;
&#xD;
               2. Any other known autoimmune disease that, in the opinion of the investigator,&#xD;
                  would interfere with an accurate assessment of clinical symptoms of myasthenia&#xD;
                  gravis or put the participant at undue risk.&#xD;
&#xD;
               3. History of malignancy unless deemed cured by adequate treatment with no evidence&#xD;
                  of recurrence for â‰¥3 years before the first administration of the investigational&#xD;
                  medicinal product (IMP). Participants with the following cancers can be included&#xD;
                  at any time:&#xD;
&#xD;
                    -  Adequately treated basal cell or squamous cell skin cancer&#xD;
&#xD;
                    -  Carcinoma in situ of the cervix&#xD;
&#xD;
                    -  Carcinoma in situ of the breast&#xD;
&#xD;
                    -  Incidental histological findings of prostate cancer (TNM Classification of&#xD;
                       Malignant Tumors stage T1a or T1b)&#xD;
&#xD;
               4. Clinical evidence of other significant serious diseases, or have had a recent&#xD;
                  major surgery, or who have any other condition that, in the opinion of the&#xD;
                  investigator, could confound the results of the trial or put the participant at&#xD;
                  undue risk&#xD;
&#xD;
          4. Worsening muscle weakness secondary to concurrent infections or medications&#xD;
             (aminoglycosides, fluoro-quinolones, beta-blockers, etc).&#xD;
&#xD;
          5. A documented lack of clinical response to plasma exchange (PLEX).&#xD;
&#xD;
          6. Received a live or live-attenuated vaccine fewer than 28 days before screening.&#xD;
             Receiving an inactivated, subunit, polysaccharide, or conjugate vaccine any time&#xD;
             before screening is not exclusionary.&#xD;
&#xD;
          7. Received a thymectomy &lt;3 months before screening or 1 is planned to be performed&#xD;
             during the trial period.&#xD;
&#xD;
          8. The following results from these diagnostic assessments will be considered&#xD;
             exclusionary:&#xD;
&#xD;
               1. Positive serum test at screening for an active viral infection with any of the&#xD;
                  following conditions:&#xD;
&#xD;
                    -  Hepatitis B virus (HBV) that is indicative of an acute or chronic infection&#xD;
&#xD;
                    -  Hepatitis C virus (HCV) based on HCV antibody assay&#xD;
&#xD;
                    -  Human immunodeficiency virus (HIV) associated with a CD4 count &lt;200&#xD;
                       cells/mm3 with an acquired immunodeficiency syndrome (AIDS)-defining&#xD;
                       condition, such as: Cytomegalovirus retinitis with loss of vision,&#xD;
                       Pneumocystis jiroveci pneumonia, chronic intestinal cryptosporidiosis,&#xD;
                       HIV-related encephalopathy, Mycobacterium tuberculosis (pulmonary or&#xD;
                       extrapulmonary), or invasive cervical cancer&#xD;
&#xD;
               2. Positive nasopharyngeal swab polymerase chain reaction (PCR) test for severe&#xD;
                  acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at screening.&#xD;
&#xD;
          9. Using the following prior or concomitant therapies:&#xD;
&#xD;
               1. Use of an investigational product within 3 months or 5 half-lives (whichever is&#xD;
                  longer) before the first dose of the investigational medicinal product (IMP).&#xD;
&#xD;
               2. Use of any monoclonal antibody within the 6 months before the first dose of the&#xD;
                  investigational medicinal product (IMP).&#xD;
&#xD;
               3. Use of intravenous immunoglobulin (IVIg), administered subcutaneously or&#xD;
                  intramuscularly, or Plasma exchange (PLEX) within 4 weeks before screening.&#xD;
&#xD;
         10. Total immunoglobulin (IgG) levels &lt;6 g/L below the lower limit of normal (LLN)&#xD;
             according to the reference ranges of the central laboratory for participant by sex and&#xD;
             age at screening.&#xD;
&#xD;
         11. A known hypersensitivity reaction to efgartigimod or any of its excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio Guglietta, MD</last_name>
    <phone>857-350-4834</phone>
    <email>ClinicalTrials@argenx.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myasthenia Gravis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

